NYSE$AVTR

Avantor Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Avantor's financial performance reflected a challenging biopharma market, with strategic actions taken to offset headwinds and invest in long-term growth.

Avantor reported a decrease in net sales by 8.7% to $1.74 billion, with a core organic decline of 6.5%. Net income was ($7.3) million, while adjusted EBITDA reached $343.0 million. The company's diluted GAAP EPS was ($0.01), and adjusted EPS was $0.28. Operating cash flow was $168.2 million, and free cash flow was $138.1 million.

  • Net sales decreased by 8.7% to $1.74 billion, with a core organic decline of 6.5%.
  • Adjusted EBITDA was $343.0 million with a margin of 19.7%.
  • Diluted GAAP EPS was ($0.01), and adjusted EPS was $0.28.
  • Operating cash flow was $168.2 million, and free cash flow was $138.1 million.

Headline financials

Total Revenue

$1.74B

Previous: $1.91B-8.7%
EPS (adj)

$0.28

Previous: $0.37-24.3%
Adjusted EBITDA

$343M

Previous: $404M-15.1%
Adjusted EBITDA Margin

19.7%

Previous: 21.2%-7.1%
Capital Expenditures

-$58.1M

Previous: -$60.8M+4.4%
Free Cash Flow

-$65.4M

Previous: $127M-151.7%
Net Income

-$7.3M

Previous: $187M-103.9%
Operating Income

$71.7M

Previous: $296M-75.7%
Gross Profit

$590M

Previous: $648M-8.9%
Cash & Equivalents

$236M

Previous: $238M-0.5%
Total Assets

$13.1B

Previous: $13.4B-2.7%
Stock-Based Comp

$9.2M

Previous: $13M-29.2%

Revenue & EPS history

Avantor · Revenue · Quarterly

$1.74B

Q2 2023-8.7%vs Q2 2022
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Forward guidance

No forward guidance was provided in the press release.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-0.6%

Avg return

Earnings day

-0.9%

Avg return

5 days after

+1.3%

Avg return

30 days after

47%

15 / 32 earnings

Positive

+21.7%

Q1 2020

Best reaction

-23.2%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+1.5%+16.0%
Q4 2025-13.6%-17.6%-28.9%
Q3 2025-23.2%-22.5%-22.2%
Q1 2025-16.6%-16.2%-18.1%
Q4 2024-11.7%-16.8%-19.4%
Q3 2024-2.7%-3.5%-10.7%
Q2 2024+15.0%+17.2%+12.4%
Q1 2024-4.3%-2.9%-4.0%
Q4 2023+8.6%+7.3%+13.3%
Q3 2023-12.1%-10.8%+4.1%
Q2 2023-9.9%-7.9%-4.6%
Q1 2023+8.0%+7.8%+10.2%
Q4 2022-5.9%-1.9%+0.9%
Q3 2022-1.8%-6.1%+4.4%
Q2 2022-8.6%-7.9%-19.6%
Q1 2022+8.4%+7.4%+12.1%
Q4 2021-2.9%-3.6%-13.5%
Q3 2021+9.3%+7.9%+7.3%
Q2 2021+0.3%+0.9%+4.8%
Q1 2021-1.4%-5.7%-3.0%
Q4 2020-2.2%-1.9%-9.9%
Q3 2020-5.5%-5.9%+5.3%
Q2 2020+16.6%+18.3%+16.0%
Q1 2020+21.7%+22.8%+37.4%
Q4 2019-11.4%-7.5%-21.5%
Q3 2018+2.7%-4.2%+17.4%
Q3 2019+2.7%-4.2%+17.4%
Q2 2019+4.2%+5.2%+7.3%
Q1 2018+4.2%+5.2%+7.3%
Q2 2018+4.2%+5.2%+7.3%
Q1 2019+4.2%+5.2%+7.3%
Q4 2018+4.2%+5.2%+7.3%
Q4 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro